Pazopanib in the treatment of advanced renal cell carcinoma

Pazopanib is an oral multitargeted tyrozine kinase inhibitor that is used in advanced renal cancer in most countries of the world. Pazopanib inhibits tyrosine kinase receptors involved in tumor angiogenesis and proliferation, including VEGF, platelet-derived growth factor (PDGF) and stem cell growth...

Full description

Bibliographic Details
Published in:	Медицинский совет
Main Authors:	M. I. Volkova, A. S. Olshanskaya
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2018-11-01
Subjects:	pazopanib sorafenib sunitinib axitinib bevacizumab everolimus disseminated renal cell carcinoma targeted therapy survival
Online Access:	https://www.med-sovet.pro/jour/article/view/2753

Similar Items

Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System
by: Dong Hyuk Kang, et al.
Published: (2023-05-01)

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
by: Xinan Sheng, et al.
Published: (2020-03-01)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
by: Asim Amin, et al.
Published: (2018-10-01)

Second Line Therapies After Tyrosine Kinase Inhibitory in Metastatic Renal Cell Carcinoma
by: Ender DOĞAN, et al.
Published: (2025-04-01)

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
by: Sylvie Négrier, et al.
Published: (2017-08-01)

Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast
by: Benjamin Garmezy, et al.
Published: (2024-10-01)

Prognostic Factors and Treatment Outcomes in Renal Cell Carcinoma: A Comprehensive Analysis
by: Ömer Faruk ELÇİÇEK, et al.
Published: (2024-09-01)

Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment
by: Utku Oflazoglu, et al.
Published: (2016-08-01)

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury
by: Maud Maillard, et al.
Published: (2022-09-01)

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
by: Huan Deng, et al.
Published: (2019-06-01)

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
by: Takashi Kawahara, et al.
Published: (2019-07-01)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
by: Nicolas S. H. Xander, et al.
Published: (2023-06-01)

Prognostic markers and new, innovative treatments in renal cell carcinoma
by: Secasan Ciprian
Published: (2009-01-01)

Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma
by: Omer Faruk Kuzu, et al.
Published: (2025-07-01)

More than 10 years survival with sequential therapy in a patient with advanced renal cell carcinoma: a case report
by: J.L. Yuan, et al.
Published: (2014-10-01)

More than 10 years survival with sequential therapy in a patient with advanced renal cell carcinoma: a case report
by: J.L. Yuan, et al.
Published: (2015-01-01)

Axitinib in sequential therapy in metastatic renal cell carcinoma
by: Agata Kuchar, et al.
Published: (2015-05-01)

Beyond the rare: a case of pseudomyogenic hemangioendothelioma treated sequentially with everolimus, denosumab, and pazopanib
by: Douglas Dias e Silva, et al.
Published: (2024-12-01)

Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
by: Wen Cai, et al.
Published: (2017-08-01)

Pazopanib as first-line therapy for patients with metastatic kidney cancer
by: B. Ya. Alekseev, et al.
Published: (2018-07-01)

Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach
by: Diogo Alpuim Costa, et al.
Published: (2017-11-01)

The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment
by: B. Ya. Alekseev, et al.
Published: (2021-06-01)

Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study
by: Erman Mustafa, et al.
Published: (2021-09-01)

Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy
by: Akinori Nukui, et al.
Published: (2017-05-01)

Melatonin acts synergistically with pazopanib against renal cell carcinoma cells through p38 mitogen-activated protein kinase-mediated mitochondrial and autophagic apoptosis
by: Chien-Pin Lai, et al.
Published: (2023-07-01)

Brazilian data of renal cell carcinoma in a public university hospital
by: Pedro Aguiar Junior, et al.
Published: (2016-02-01)

Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient
by: Camillo Porta, et al.
Published: (2017-06-01)

Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model
by: Amber Kempton, et al.
Published: (2018-08-01)

Short-Term Efficacy and Safety of Pazopanib Combined with Chemotherapy in Treatment of Advanced Synovial Sarcoma
by: Jing WANG, et al.
Published: (2025-04-01)

Durable Response to Pazopanib in a Patient with Fumarate Hydratase-Mutant Tubulocystic Renal Cell Carcinoma
by: Anjum Othman, et al.
Published: (2023-04-01)

Phototoxic Reaction Induced by Pazopanib
by: Siriorn Udompanich, et al.
Published: (2018-11-01)

Spontaneous Dramatic Regression of Clear Cell Renal Cell Carcinoma After Pazopanib-Induced Severe Systemic Inflammatory Syndrome: A Case Report and Literature Review
by: Chi Hyuk Oh, et al.
Published: (2025-04-01)

Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth
by: Ke Wang, et al.
Published: (2024-01-01)

Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report
by: Huimin Zhang, et al.
Published: (2024-02-01)

Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study
by: P. Barthelemy, et al.
Published: (2025-09-01)

First-line pazopanib in patients with metastatic epithelioid hemangioendothelioma: a retrospective single-center analysis
by: Anton Burkhard-Meier, et al.
Published: (2025-04-01)

Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
by: Charles McCrea, et al.
Published: (2018-02-01)

Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma
by: Daniel Y.C. Heng, et al.
Published: (2011-12-01)

Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma
by: Daniel Y.C. Heng, et al.
Published: (2011-12-01)

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
by: Irina Proskorovsky, et al.
Published: (2018-12-01)